Literature DB >> 28153092

GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration.

Jiusheng Deng1, Yanqiu Li2, Andrea Pennati2, Shala Yuan2, Jian Hui Wu3, Edmund K Waller2, Jacques Galipeau4.   

Abstract

Hematopoietic stem cells (HSCs) have the capacity to self-renew and differentiate into hematopoietic cells and have been utilized to replace diseased bone marrow for patients with cancers and blood disorders. Although remarkable progress has been made in developing new tools to manipulate HSCs for clinic use, there is still no effective method to expand HSCs in vivo for quick repopulation of hematopoietic cells following sublethal irradiation. We have recently described a novel synthetic cytokine that is derived from the fusion of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4; named as GIFT4), and we have now discovered that GIFT4 fusokine promotes long-term hematopoietic regeneration in a B cell-dependent manner. We found that GIFT4 treatment triggered a robust expansion of endogenous bone marrow HSCs and multipotent progenitors in vivo. Delivery of GIFT4 protein together with B cells rescued lethally irradiated mice. Moreover, adoptive transfer of autologous or allogeneic GIFT4-treated B cells (GIFT4-B cells) enhanced long-term hematopoietic recovery in radiated mice and prevented the mice from irradiation-induced death. Our data suggest that GIFT4 as well as GIFT4-B cells could serve as means to augment HSC engraftment in the setting of bone marrow transplantation for patients with hematological malignancy.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B cells; fusion cytokine; hematopoietic stem cells

Mesh:

Substances:

Year:  2017        PMID: 28153092      PMCID: PMC5368424          DOI: 10.1016/j.ymthe.2016.11.013

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  57 in total

1.  Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling.

Authors:  Elizabeth Csaszar; Daniel C Kirouac; Mei Yu; WeiJia Wang; Wenlian Qiao; Michael P Cooke; Anthony E Boitano; Caryn Ito; Peter W Zandstra
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

2.  Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.

Authors:  Anthony E Boitano; Jian Wang; Russell Romeo; Laure C Bouchez; Albert E Parker; Sue E Sutton; John R Walker; Colin A Flaveny; Gary H Perdew; Michael S Denison; Peter G Schultz; Michael P Cooke
Journal:  Science       Date:  2010-08-05       Impact factor: 47.728

3.  Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

Authors:  Benjamin Terrier; Marc Ittah; Léa Tourneur; Fawzia Louache; Vassili Soumelis; Frédéric Lavie; Nicole Casadevall; Sophie Candon; Aurélie Hummel; Xavier Mariette; Agnès Buzyn
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

4.  Granulocyte Colony-Stimulating Factor Induces Osteoblast Inhibition by B Lymphocytes and Osteoclast Activation by T Lymphocytes during Hematopoietic Stem/Progenitor Cell Mobilization.

Authors:  Sidan Li; Tianshou Li; Yongbing Chen; Yinchao Nie; Changhong Li; Lanting Liu; Qiaochuan Li; Lugui Qiu
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-16       Impact factor: 5.742

5.  A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex.

Authors:  Moutih Rafei; Jian Hui Wu; Borhane Annabi; Laurence Lejeune; Moïra François; Jacques Galipeau
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

6.  Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression.

Authors:  H E Broxmeyer; B Sherry; S Cooper; L Lu; R Maze; M P Beckmann; A Cerami; P Ralph
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

7.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.

Authors:  Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

8.  The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation.

Authors:  Claudia Penafuerte; Norma Bautista-Lopez; Mohamed-Rachid Boulassel; Boulassel Mohamed-Rachid; Jean-Pierre Routy; Jacques Galipeau
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

9.  Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.

Authors:  Tamiko R Katsumoto; Jennifer Duda; Andrew Kim; Zabihullah Wardak; Glenn Dranoff; D Wade Clapp; Kevin Shannon
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

10.  BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.

Authors:  B I Lord; E Marshall; L B Woolford; M G Hunter
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more
  2 in total

1.  Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Authors:  Maite Alvarez; Antonio Pierini; Federico Simonetta; Jeanette Baker; Kristina Maas-Bauer; Toshihito Hirai; Robert S Negrin
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

2.  Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway.

Authors:  Xiaofeng Li; Jiapo Wang; Weimin Wu; Hao Gao; Na Liu; Guangxi Zhan; Li Li; Lingfei Han; Xiaoqing Guo
Journal:  FEBS J       Date:  2020-04-17       Impact factor: 5.542

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.